SML1682

CDN1163

≥98% (HPLC), SERCA activator, powder

• Sinónimos: 4-(1-Methylethoxy)-N-(2-methyl-8-quinolinyl)-benzamide
• Fórmula empírica (notación de Hill): C₂₀H₂₀N₂O₂
• Número CAS: 892711-75-0
• Peso molecular: 320.39
• UNSPSC Code: 12352200
• PubChem Substance ID: 329826012
• NACRES: NA.77
• MDL number: MFCD07177494
• Assay: ≥98% (HPLC)
• Form: powder

Propiedades

• Nombre del producto: CDN1163, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 5 mg/mL, clear (warmed)
• storage temp.: 2-8°C
• SMILES string: CC1=NC2=C(NC(C3=CC=C(OC(C)C)C=C3)=O)C=CC=C2C=C1
• InChI: 1S/C20H20N2O2/c1-13(2)24-17-11-9-16(10-12-17)20(23)22-18-6-4-5-15-8-7-14(3)21-19(15)18/h4-13H,1-3H3,(H,22,23)
• InChI key: GVGVYDCVFBGALZ-UHFFFAOYSA-N

Descripción

Biochem/physiol Actions

CDN1163 is an allosteric activator of sarco/ endoplasmic reticulum Ca2+-ATPase (SERCA) that potently lowered fasting blood glucose, improved glucose tolerance and ameliorated hepatosteatosis in ob/ob mice. Additionally CDN1163 induces significant reduction in adipose tissue weight with no change in lean mass in ob/ob mice. CDN1163 has no effect on glucose levels or body weight in lean control mice.

CDN1163 is an allosteric activator of sarco/ endoplasmic reticulum Ca2+-ATPase (SERCA).

CDN1163 treatment declined the hepatic expression of genes implicated in gluconeogenesis and lipogenesis as well as attenuated endoplasmic reticulum (ER) stress response and ER stress-induced apoptosis. CDN1163 interacts with sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) and enhances ER Ca²⁺ content.

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable